文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[脓毒症:对其发病机制与治疗的新见解]

[Sepsis: new insights into its pathogenesis and treatment].

作者信息

Wiersinga W Joost, van der Poll Tom

机构信息

Academisch Medisch Centrum, afd. Inwendige Geneeskunde, Center for Infection and Immunity Amsterdam, Center for Experimental Molecular Medicine, Amsterdam, The Netherlands.

出版信息

Ned Tijdschr Geneeskd. 2010;154:A1130.


DOI:
PMID:20170566
Abstract

The incidence of sepsis is increasing worldwide, yet the mortality rate has barely decreased during the past decades and remains unacceptably high at between 20% - 40%. New knowledge on host-pathogen interactions has greatly increased our insights in the pathogenesis of sepsis. It is now clear that sepsis is not only characterized by proinflammation but also by immunosuppression. Here we give an overview of the functional interactions between bacteria and our immune system. Microbial virulence factors, pathogen recognition receptors, activation of coagulation, apoptosis and a wide range of new mediators of sepsis play a role in these interactions. Implementation of evidence-based guidelines for the rapid diagnosis and adequate treatment of sepsis has been shown to be instrumental in improving survival in sepsis. The increasing insights into the pathogenesis of sepsis have identified a whole new range of potential drugs which are currently being tested in clinical trials.

摘要

全球范围内脓毒症的发病率正在上升,但在过去几十年中死亡率几乎没有下降,仍高达20% - 40%,令人难以接受。关于宿主 - 病原体相互作用的新知识极大地增进了我们对脓毒症发病机制的理解。现在很清楚,脓毒症不仅以炎症反应为特征,还伴有免疫抑制。在此,我们概述细菌与我们免疫系统之间的功能相互作用。微生物毒力因子、病原体识别受体、凝血激活、细胞凋亡以及众多脓毒症新介质在这些相互作用中发挥作用。实施基于证据的脓毒症快速诊断和充分治疗指南已被证明有助于提高脓毒症患者的生存率。对脓毒症发病机制的深入了解已确定了一系列全新的潜在药物,目前这些药物正在临床试验中进行测试。

相似文献

[1]
[Sepsis: new insights into its pathogenesis and treatment].

Ned Tijdschr Geneeskd. 2010

[2]
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.

Dis Mon. 2004-4

[3]
[Development of antituberculous drugs: current status and future prospects].

Kekkaku. 2006-12

[4]
[Sepsis in the critically-ill patient].

Ugeskr Laeger. 2007-2-19

[5]
New insights into the pathogenesis and therapy of sepsis and septic shock.

Curr Clin Top Infect Dis. 2001

[6]
New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis.

J Infect. 2011-8-9

[7]
Sepsis: a roadmap for future research.

Lancet Infect Dis. 2015-4-19

[8]
[Neonatal sepsis caused by Streptococcus agalactiae. What should be done?].

An Esp Pediatr. 1998-3

[9]
The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.

Int J Med Microbiol. 2007-9

[10]
Postoperative bacterial/fungal infections: a challenging problem in critically ill patients after abdominal surgery.

Dig Surg. 2007

引用本文的文献

[1]
Yohimbine promotes cardiac NE release and prevents LPS-induced cardiac dysfunction via blockade of presynaptic α2A-adrenergic receptor.

PLoS One. 2013-5-14

[2]
Nitric oxide-dependent killing of aerobic, anaerobic and persistent Burkholderia pseudomallei.

Nitric Oxide. 2012-4-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索